Mitochondrial DNA copy number and incident atrial fibrillation
verfasst von:
Di Zhao, Traci M. Bartz, Nona Sotoodehnia, Wendy S. Post, Susan R. Heckbert, Alvaro Alonso, Ryan J. Longchamps, Christina A. Castellani, Yun Soo Hong, Jerome I. Rotter, Henry J. Lin, Brian O’Rourke, Nathan Pankratz, John A. Lane, Stephanie Y. Yang, Eliseo Guallar, Dan E. Arking
Mechanistic studies suggest that mitochondria DNA (mtDNA) dysfunction may be associated with increased risk of atrial fibrillation (AF). The association between mtDNA copy number (mtDNA-CN) and incident AF in the general population, however, remains unknown.
Methods
We conducted prospective analyses of 19,709 participants from the Atherosclerosis Risk in Communities Study (ARIC), the Multi-Ethnic Study of Atherosclerosis (MESA), and the Cardiovascular Health Study (CHS). mtDNA-CN from the peripheral blood was calculated from probe intensities on the Affymetrix Genome-Wide Human single nucleotide polymorphisms (SNP) Array 6.0 in ARIC and MESA and from multiplexed real-time quantitative polymerase chain reaction (qPCR) in CHS. Incident AF cases were identified through electrocardiograms, review of hospital discharge codes, Medicare claims, and death certificates.
Results
The median follow-up time was 21.4 years in ARIC, 12.9 years in MESA, and 11.0 years in CHS, during which 4021 participants developed incident atrial fibrillation (1761 in ARIC, 790 in MESA, and 1470 in CHS). In fully adjusted models, participants with the lowest quintile of mitochondria DNA copy number had an overall 13% increased risk (95% CI 1 to 27%) of incident atrial fibrillation compared to those with the highest quintile. Dose-response spline analysis also showed an inverse association between mitochondria DNA copy number and hazard for atrial fibrillation for all three cohorts. These associations were consistent across subgroups.
Conclusions
Mitochondria DNA copy number was inversely associated with the risk of AF independent of traditional cardiovascular risk factors. These findings implicate mitochondria DNA copy number as a novel risk factor for atrial fibrillation. Further research is warranted to understand the underlying mechanisms and to evaluate the role of mitochondria DNA copy number in the management of atrial fibrillation risk.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARIC
Atherosclerosis Risk in Communities Study
ATP
Adenosine triphosphate
AF
Atrial fibrillation
CVD
Cardiovascular disease
CHS
Cardiovascular Health Study
DNA
Deoxyribonucleic acid
MESA
Multi-Ethnic Study of Atherosclerosis
mtDNA-CN
Mitochondria deoxyribonucleic acid copy number
ROS
Reactive oxygen species
SNP
Single nucleotide polymorphisms
Background
Atrial fibrillation (AF) is the most common form of clinical cardiac arrhythmia, with rising prevalence and incidence worldwide. The lifetime risk of developing AF ranges from 20 to 37% in Whites and Blacks [1‐3], and it is estimated that the number of adults with AF will double in the USA by the year 2050, affecting more than 8 million people [4]. AF imposes considerable mortality and morbidity risks related to cardiovascular events and thromboembolism and is associated with tremendous healthcare costs [5, 6]. The high lifetime risk and adverse consequences of AF highlight the critical need for identifying novel risk markers that may provide insights into AF prevention and treatment.
Mitochondria generate energy for the cell through converting nutrients and oxygen into adenosine triphosphate (ATP) [7]. Unlike other organelles, mitochondria have their own circular DNA (mtDNA), which encodes essential genes for oxidative phosphorylation. Each cell contains on average 103 to 104 copies of mtDNA, with variations by cell type and development phase [8]. Mitochondrial DNA copy number (mtDNA-CN) is proportional to the transcription of mitochondrial genes and is a marker of mitochondrial dysfunction [9]. Indeed, reduced mtDNA-CN from the peripheral blood is associated with adverse cardiovascular disease (CVD) events including heart failure, all-cause mortality, sudden cardiac death, and atherosclerotic CVD [10‐13], as well as with CVD risk factors, including hypertension, diabetes, atherosclerosis, and chronic kidney disease [14‐16].
Anzeige
Emerging evidence from mechanistic studies suggests that mtDNA dysfunction may be associated with an increased risk of AF through reduced ATP production and elevated reactive oxygen species [17, 18]. The association between mtDNA-CN and incident AF in the general population, however, remains unknown. In the present study, we examined the prospective association between baseline mtDNA-CN and the risk of incident AF among participants from 3 community-based prospective cohort studies: the Atherosclerosis Risk in Communities (ARIC) study, the Multi-Ethnic Study of Atherosclerosis (MESA), and the Cardiovascular Health Study (CHS).
Methods
Study population
ARIC is a prospective cohort study of 15,792 men and women 45–64 years of age at baseline (1987–1989) [19]. Participants were randomly selected from 4 communities in the USA: Forsyth County, NC; Jackson, MS; Minneapolis suburbs, MN; and Washington County, MD. We excluded participants who reported race other than Black or White (n = 48), Blacks from the Minnesota and Maryland centers because the numbers are too small for adequate adjustment or within-community comparisons (n = 55), and participants with prevalent CHD (n = 667) or prevalent AF at the time of mtDNA-CN measurement (n = 292). We further excluded participants whose mtDNA-CN was not measured due to sample or measurement availability (n = 4259) and those missing other covariates (n = 322). The final sample included 10,149 participants (Fig. 1).
Fig. 1
Flowchart of study participants
×
MESA is a prospective cohort study of 6814 men and women aged 45–84 years of age who were free of clinical cardiovascular disease (CVD) at the baseline visit (2000–2002) [20]. We excluded participants whose mtDNA-CN was not measured due to sample or technique availability (n = 898), who had no information on AF during follow-up (n = 82), or who were missing other covariates (n = 53). The final study sample included 5781 participants.
CHS is a prospective cohort study of 5888 men and women aged 65 years and older [21]. The original cohort of 5201 participants was recruited in 1989–1990 from random samples of Medicare eligibility lists, and an additional predominantly African-American cohort of 687 participants was recruited in 1992–1993. We excluded participants who reported race other than Black or White (n = 39), who lacked genetic consent (n = 273), and who had prevalent CHD (n = 1106) or prevalent AF at the time of mtDNA-CN measurement (n = 123). After further excluding participants whose mtDNA-CN was not measured due to sample or technique availability (n = 471), and those missing other covariates (n = 97), the final study sample included 3779 participants.
Anzeige
mtDNA copy number
In ARIC, DNA for mtDNA-CN analysis was collected at visit 1 (1987–1989) for 389 participants (3.8%), at visit 2 (1990–1992) for 8221 participants (81.0%), at visit 3 (1993–1995) for 1485 participants (14.6%), and at visit 4 for (1996–1998) for 54 participants (0.5%). In MESA and CHS, DNA for mtDNA-CN analysis was collected at visit 1. The visit of DNA collection was considered as the baseline visit for each participant in the present analysis.
In ARIC and MESA, DNA samples were isolated from buffy coat and genotyped using Affymetrix Genome-Wide Human SNP Arrays 6.0 (the Genvisis software package [www.genvisis.org]) [11, 12, 22]. Mitochondrial SNPs were collected across all samples and were signaled with high-quality mitochondrial probes. Unadjusted mtDNA-CN was determined as the median of normalized probe intensity differences across all mitochondrial SNPs. To correct for technical artifacts, batch effects, DNA quality, and starting DNA quantity, we applied surrogate variable analysis (ARIC) and principal component analysis (MESA) to probe intensities of 43,316 Affymetrix autosomal SNPs [23]. We then calculated the residuals of a linear regression model with unadjusted mtDNA-CN as the dependent variable and age, sex, enrollment center, technical covariates, and white blood cell (WBC) count as independent variables in ARIC, and age, sex, collection center, race and principal components as independent variables in MESA. In ARIC, WBC count was missing in 14.9% of participants, and we imputed missing WBC as the study mean. In MESA, the rank-based inverse normal transformation was also performed to reduce the impact of outliers.
In CHS, mtDNA-CN was measured using multiplexed real-time quantitative polymerase chain reaction (qPCR) utilizing ABI TaqMan chemistry (Applied Biosystems) [12]. We calculated residuals using a linear mixed effect model stratified by race, with unadjusted mtDNA-CN as the dependent variable, and age, sex, collection site (fixed effects), and qPCR plate (random effect) as independent variables. The mtDNA-CN residuals were standardized within each study (mean of 0 and standard deviation of 1), and this measure was used as our estimate of mtDNA-CN. The normal distribution of mtDNA-CN residuals depended on the goodness of fit of the model. The residuals were standardized within each study (mean of 0 and standard deviation of 1), and this measure was used as our estimate of mtDNA-CN.
Atrial fibrillation
In ARIC, AF cases were identified through December 31, 2014, from three sources: electrocardiograms (ECGs) performed during study visits, review of hospital discharge codes, and death certificates [24]. At each study exam, a supine 12-lead resting ECG was performed and transmitted to the ARIC ECG Reading Center (Epidemiological Cardiology Research Center, Wake Forest School of Medicine, Winston Salem, NC) for automatic coding with E Marquette 12-SL program (GE Marquette, Milwaukee, WI). AF or atrial flutter was detected automatically by a computer and confirmed by a cardiologist. Hospitalization information during follow-up was obtained through annual follow-up phone calls and surveillance of local hospitals. Trained abstractors collected hospital discharge codes. AF cases detected in the same hospitalization with open cardiac surgery were excluded. The validity of identifying AF from hospital discharge codes has been established in epidemiological studies [24, 25]. The presence of AF was identified if ICD-9-CM codes 427.31 (AF) or 427.32 (atrial flutter) were listed. Finally, AF was identified from death certificates if ICD-9 427.3 or ICD-10 I48 codes were listed as a cause of death. The AF date was determined as the date of the first ECG with AF (4%), the time of first hospital discharge with AF codes (96%), or when AF was listed as a cause of death (0.1%), whichever occurred first.
In MESA, AF cases were identified through December 31, 2014, from three sources: hospital discharge diagnosis codes, Medicare claims data, and study ECGs [26]. Hospitalization information during follow-up was obtained through phone calls every 9–12 months, and medical records and discharge diagnoses were obtained subsequently. Additionally, for participants enrolled in fee-for-service Medicare, AF diagnoses were identified from inpatient, outpatient, and physician claims. Study ECGs from visit 5 (2010–2012) were also used to identify incident AF.
In CHS, AF cases were identified through December 31, 2012, from three sources: annual ECGs at each study visit through 1999, discharge diagnoses for all hospitalizations (ICD-9-CM code 427.31 or 427.32), and for those enrolled in fee-for-service Medicare, from inpatient, outpatient, or physician claims in Medicare data [25]. The date of AF diagnosis was based on the date of the first ECG indicating AF, the time of the first hospital discharge with AF codes, or the time of the first qualifying outpatient or physician claim, whichever occurred first.
Other covariates
The measurement of other covariates in the three cohorts has been described previously [19‐21]. Age, sex, race/ethnicity, alcohol intake, smoking status, physical activity, and medication use were self-reported. Alcohol consumption was categorized into never, former, and current for ARIC and MESA and into non-current and current for CHS. Body mass index was calculated as weight (kg) divided by height (m) squared. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or current use of anti-hypertension medication. Physical activity was assessed via a modified Baecke Questionnaire in ARIC (scales 1–5), a modified Minnesota Leisure Time Physical Activity Questionnaire in CHS (scales 1–4), and as the total amount of intentional moderate or vigorous exercise performed in a usual week in MESA (MET-min/week). Prevalent heart failure was defined by hospital records, physician diagnosis, or self-reported history of treatment.
Plasma total cholesterol, HDL cholesterol, fasting glucose, and creatinine were measured in each study are previously described [19‐21]. N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured at visits 2 and 4 using an electrochemiluminescent immunoassay in ARIC and at baseline using the Elecsys 2010 analyzer in MESA and CHS. Diabetes was defined as fasting glucose ≥ 126 mg/dL, non-fasting glucose ≥ 200 mg/dL, or use of glycemic control medication. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation ARIC and MESA [27], and Modification of Diet in Renal Disease (CKD-MDRD) equation in CHS [27]. Kidney disease was defined as eGFR < 60 mL/min/1.73 m2.
Anzeige
Statistical analyses
Follow-up started from the baseline visit and continued until the development of AF, death, dropout, or through December 31, 2014, in ARIC and MESA or December 31, 2012, in CHS, whichever occurred first. mtDNA-CN was categorized into cohort-specific quintiles. We used a Cox proportional hazards model to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between mtDNA-CN and incident AF in each cohort. HRs compared quintiles 1st to 4th with the 5th quintile (reference). Linear trends across quintiles were tested by including a variable containing the median mtDNA-CN level of each quintile in the models. We also modeled mtDNA-CN as a continuous variable and estimated the HR comparing the 10th to the 90th percentile of mtDNA-CN. In addition, to evaluate non-linear dose-response relationships between mtDNA-CN and incident AF, we modeled mtDNA-CN as restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles of its distribution. Finally, we tested for potential interactions by age, sex, race, smoking, alcohol intake, BMI, hypertension, diabetes, and kidney disease.
All analyses were conducted separately in each cohort, and cohort-specific HRs were combined using a fixed-effects meta-analysis approach. In each cohort, we used 4 multivariate models with progressive degrees of adjustment. Model 1 was adjusted for age, sex, and race enrollment center groups. Model 2 was further adjusted for body mass index, height, smoking, alcohol intake, and physical activity. Model 3 was further adjusted for total and HDL cholesterol, cholesterol medication, hypertension, diabetes, and prevalent HF. Model 4 was further adjusted for NT-proBNP. As additional analyses, we computed missing mtDNA-CN in ARIC using multiple imputation with chained equation (MICE) based on age, sex, race/center groups, BMI, height, physical activity, total cholesterol, HDL cholesterol, hyperlipidemia medication, eGFR, BNP, smoking, alcohol consumption, diabetes, hypertension, and HF. We used a series of 20 imputations to derive the additional estimates. We also conducted a post hoc analysis using the inverse probability of attrition weighting (IPAW) to account for potential informative death censoring [28‐30]. Time-varying predicted probabilities of the remaining alive at a 6-month binned follow-up interval for each participant were calculated using the Cox proportional hazards model with death as the outcome and all variables in model 3 as independent variables. Attrition weights were calculated as the inverse of the predicted probability.
Statistical analyses were performed using Stata version 15 for ARIC and MESA study and Stata version 12 for the CHS study (StataCorp LP, College Station, TX). All p values were 2-sided, and statistical significance was declared at p < 0.05.
Results
The study included 19,709 participants in total (10,149 from ARIC, 5781 from MESA, and 3779 from CHS). The mean (standard deviation) age of study participants was 57.2 (5.9), 62.3 (10.3), and 72.2 (5.3) for ARIC, MESA, and CHS, respectively (Table 1); 43.5% of the participants were men (ARIC 42.4%, MESA 47.8%, and CHS 39.9%), and 69.4% participants were Whites (ARIC 79.0%, MESA 42.6%, and CHS 84.7%). Participants with lower mtDNA-CN were more likely to be current smokers, to have higher NT-proBNP, and to have diabetes and prevalent CKD (Additional files: Tables S1-S3). Age, male gender, BMI, current smoking, diabetes, and NT-proBNP are the most strongly associated with the risk of incident AF (Table 2).
Table 1
Baseline characteristics of study participants
Characteristic
ARIC
MESA
CHS
N
10,149
5781
3779
Age (years)
57.2 (5.9)
62.3 (10.3)
72.2 (5.3)
Male
4307 (42.4)
2762 (47.8)
1506 (39.9)
Race
White
8018 (79.0)
2464 (42.6)
3199 (84.7)
Black
2131 (21.0)
1387 (24.0)
580 (15.3)
Chinese-American
–
764 (13.2)
–
Hispanic
–
1166 (20.2)
–
Smoking
Never
4020 (39.6)
2925 (50.6)
1766 (46.7)
Former
3814 (37.6)
2117 (36.6)
1535 (40.6)
Current
2315 (22.8)
739 (12.8)
478 (12.6)
Current drinker
5886 (58.0)
3221 (55.7)
1927 (51.0)
Body mass index (kg/m2)
28.0 (5.5)
28.2 (5.5)
26.7 (4.7)
Total cholesterol (mg/dL)
209.8 (39.5)
194.4 (35.7)
212.9 (38.6)
HDL cholesterol (mg/dL)
50.2 (17.1)
51.0 (14.9)
55.5 (15.8)
Triglycerides (mg/dL)
115.0 (82.0, 162.0)
112.0 (78.0, 162.0)
119.0 (91.0, 162.0)
Systolic BP (mmHg)
122.0 (19.1)
126.4 (21.7)
136.3 (21.6)
Diastolic BP (mmHg)
72.2 (10.3)
71.8 (10.3)
71.2 (11.2)
NT-proBNP (pg/mL)
52.2 (29.0, 91.7)
56.0 (24.9, 115.3)
96.8 (51.4, 186.5)
Hypertension
3560 (35.1)
2569 (44.4)
2134 (56.5)
Diabetes
1413 (13.9)
700 (12.1)
510 (13.5)
Prevalent HF
395 (3.9)
–
58 (1.5)
Prevalent CKD
192 (1.9)
776 (13.4)
721 (19.1)
Values are mean (SD), number (%), or median (IQR)
Table 2
Hazard ratios for AF associated with different risk factors
ARIC
MESA
CHS
mtDNA-CN
0.94 (0.89, 0.99)
0.96 (0.89, 1.03)
0.97 (0.91,1.03)
Age, years
1.65 (1.55, 1.77)
2.22 (1.99, 2.48)
1.57 (1.46,1.68)
Sex
Female
Reference (1)
Reference (1)
Reference (1)
Male
1.29 (1.08, 1.55)
1.47 (1.16, 1.87)
0.87 (0.72,1.05)
Race
White
Reference (1)
Reference (1)
Reference (1)
Black
0.58 (0.49, 0.69)
0.67 (0.54, 0.84)
0.65 (0.53, 0.79)
Chinese-American
NA
1.40 (1.03, 1.90)
NA
Hispanic
NA
0.91 (0.70, 1.19)
NA
BMI, kg/m2
1.31 (1.24, 1.39)
1.28 (1.17, 1.40)
1.09 (1.02,1.17)
Smoking
Never
Reference (1)
Reference (1)
Reference (1)
Former
1.09 (0.95, 1.25)
1.06 (0.89, 1.25)
1.10 (0.97,1.25)
Current
1.74 (1.49, 2.02)
1.56 (1.20, 2.04)
1.23 (0.99,1.52)
Physical activity
0.98 (0.93, 1.04)
0.99 (0.90, 1.08)
0.99 (0.93,1.05)
Alcohol
Never
Reference (1)
Reference (1)
Reference (1)
Former
1.03 (0.87, 1.23)
1.21 (0.95, 1.55)
NA
Current
0.88 (0.76, 1.03)
1.15 (0.91, 1.44)
0.97 (0.87,1.07)
Total cholesterol, mg/dL
0.97 (0.92, 1.03)
1.05 (0.97, 1.14)
0.95 (0.89,1.02)
HDL cholesterol, mg/dL
0.98 (0.92, 1.05)
1.00 (0.91, 1.09)
1.05 (0.98,1.13)
Lipid-lowering medication
No
Reference (1)
Reference (1)
Reference (1)
Yes
1.09 (0.87, 1.35)
1.11 (0.92, 1.34)
1.08 (0.82,1.42)
Diabetes
No
Reference (1)
Reference (1)
Reference (1)
Yes
1.36 (1.17, 1.59)
1.20 (0.97, 1.48)
1.25 (1.06,1.48)
Hypertension
No
Reference (1)
Reference (1)
Reference (1)
Yes
1.41 (1.11, 1.79)
1.04 (0.88, 1.23)
1.32 (1.16,1.49)
eGFR, mL/min/1.73 m2
1.09 (1.02, 1.16)
1.06 (0.97, 1.16)
1.01 (0.94,1.08)
Associated with 1 standard deviation increase of continuous risk factors. Model adjusted for all variables in the table
Anzeige
The median follow-up time was 21.4 (IQR 14.8–23.3) years in ARIC, 12.9 (9.6–13.6) years in MESA, and 11.0 (5.9–17.1) years in CHS. During follow-up, 4021 participants developed incident AF (1761 in ARIC, 790 in MESA, and 1470 in CHS). The overall hazard ratios for incident AF for the 1st to 4th quintiles of mtDNA-CN compared to the 5th quintile are shown in Table 3. In the meta-analysis across the 3 cohorts using the fully adjusted model, participants in the 1st quintile of mitochondria DNA-CN had a 13% increased risk of incident AF compared to those in the 5th quintile (overall hazard ratio 1.13 [1.01, 1.27]) (Fig. 2). In models with mtDNA-CN as a continuous variable, participants at the 10th percentile of mtDNA-CN had a 13% increased risk of incident AF compared to those at the 90th percentile (overall hazard ratio 1.13 [1.04, 1.24]). Dose-response spline analysis also showed an inverse association between mtDNA-CN and AF for all three cohorts, with an approximately linear trend (the p values for non-linear spline terms were 0.20, 0.31, and 0.11 in ARIC, MESA, and CHS, respectively; Fig. 3).
Table 3
Hazard ratios for incident atrial fibrillation (AF) by quintiles of mtDNA copy number
N events/N total
IR
Model 1*
Model 2†
Model 3‡
Model 4§
ARIC
mtDNA-CN quintiles
First
399/2029
10.9
1.26 (1.09, 1.46)
1.21 (1.05, 1.40)
1.20 (1.04, 1.39)
1.17 (0.99, 1.38)
Second
355/2035
9.5
1.09 (0.94, 1.27)
1.11 (0.95, 1.29)
1.10 (0.94, 1.27)
1.18 (1.00, 1.40)
Third
319/2037
8.5
0.97 (0.83, 1.13)
0.93 (0.80, 1.09)
0.94 (0.80, 1.09)
0.89 (0.74, 1.06)
Fourth
356/2031
9.3
1.07 (0.92, 1.24)
1.08 (0.93, 1.25)
1.08 (0.93, 1.25)
1.08 (0.91, 1.28)
Fifth
332/2017
8.9
Reference
Reference
Reference
Reference
p-trend
0.002
0.008
0.01
0.03
10th vs 90th percentile
1761/10,149
9.4
1.20 (1.07, 1.34)
1.18 (1.05, 1.31)
1.16 (1.04, 1.30)
1.18 (1.04, 1.33)
MESA
mtDNA-CN quintiles
First
157/1154
12.4
1.04 (0.83, 1.30)
1.02 (0.82, 1.28)
1.01 (0.81, 1.26)
1.14 (0.90, 1.45)
Second
150/1154
11.6
1.01 (0.81, 1.27)
0.99 (0.79, 1.24)
0.97 (0.78, 1.22)
1.06 (0.83, 1.36)
Third
161/1166
12.3
1.04 (0.83, 1.30)
1.02 (0.82, 1.28)
1.02 (0.82, 1.27)
1.10 (0.87, 1.40)
Fourth
169/1159
13.1
1.08 (0.87, 1.34)
1.05 (0.84, 1.31)
1.04 (0.83, 1.29)
1.10 (0.87, 1.39)
Fifth
153/1148
11.8
Reference
Reference
Reference
Reference
p-trend
0.91
0.98
0.88
0.37
10th vs 90th percentile
790/5781
12.2
1.05 (0.88, 1.25)
1.03 (0.87, 1.23)
1.03 (0.86, 1.23)
1.12 (0.93, 1.35)
CHS
mtDNA-CN quintiles
First
283/755
32.0
1.16 (0.98,1.38)
1.16 (0.98,1.37)
1.11 (0.93,1.31)
1.08 (0.89,1.32)
Second
292/756
31.9
1.12 (0.95,1.32)
1.12 (0.95,1.32)
1.09 (0.92,1.28)
1.12 (0.92,1.35)
Third
296/756
31.8
1.10 (0.94,1.30)
1.10 (0.94,1.30)
1.08 (0.92,1.28)
1.09 (0.90,1.32)
Fourth
317/756
33.6
1.19 (1.01,1.39)
1.18 (1.00,1.39)
1.15 (0.98,1.35)
1.20 (1.00,1.45)
Fifth
282/756
29.0
Reference
Reference
Reference
Reference
p-trend
0.16
0.18
0.38
0.65
10th vs 90th percentile
1470/3779
31.6
1.12 (0.98,1.27)
1.11 (0.97,1.27)
1.07 (0.94,1.23)
1.07 (0.92,1.26)
Meta-analysis
mtDNA-CN quintiles
First
839/3938
14.4
1.18 (1.07, 1.30)
1.15 (1.05, 1.27)
1.13 (1.02, 1.25)
1.13 (1.01, 1.27)
Second
797/3945
13.4
1.09 (0.98, 1.20)
1.09 (0.99, 1.20)
1.07 (0.97, 1.18)
1.13 (1.01, 1.27)
Third
776/3959
12.9
1.03 (0.93, 1.14)
1.01 (0.92, 1.21)
1.00 (0.91, 1.11)
1.01 (0.90, 1.13)
Fourth
842/3946
13.9
1.12 (1.01, 1.23)
1.11 (1.00, 1.22)
1.10 (0.99, 1.21)
1.13 (1.01, 1.26)
Fifth
767/3921
12.8
Reference
Reference
Reference
Reference
p-trend
0.006
0.01
0.03
0.03
10th vs 90th percentile
4021/19,709
13.5
1.14 (1.06, 1.23)
1.13 (1.04, 1.22)
1.11 (1.03, 1.20)
1.13 (1.04, 1.24)
IR incidence rate (per 1000 person-years)
*Model 1: adjusted for age, sex, and race/enrollment center groups
†Model 2: further adjusted for body mass index, height, smoking, alcohol intake, and physical activity
‡Model 3: further adjusted for total and HDL cholesterol, cholesterol medication, hypertension, diabetes, prevalent heart failure, and eGFR at baseline
§Model 4: further adjusted for log-transformed NT-proBNP
Fig. 2
Hazard ratios for incident atrial fibrillation by levels of mtDNA copy number. The figure includes hazard ratios for comparing quintiles 1st to 4th with the 5th quintile (reference) of mtDNA copy number, as well as the hazard ratio for comparing the 10th to the 90th percentile of mtDNA copy number. Models were adjusted for age, sex, race/enrollment center, body mass index, height, smoking, alcohol intake, physical activity, total and HDL cholesterol, cholesterol medication, hypertension, diabetes, prevalent CHD, prevalent heart failure, eGFR, and log-transformed NT-proBNP at baseline
Fig. 3
Spline regression analysis of incident atrial fibrillation by levels of mtDNA copy number. The curves represent adjusted hazard ratios (solid line) and their 95% confidence intervals (dashed lines) based on restricted cubic splines of mtDNA copy number with knots at the 5th, 35th, 65th, and 95th percentiles of its distribution. The reference value (diamond dot) was set at the 90th percentile of the distribution. Models were adjusted for age, sex, race/enrollment center, body mass index, height, smoking, alcohol intake, physical activity, total and HDL cholesterol, cholesterol medication, hypertension, diabetes, prevalent CHD, prevalent heart failure, eGFR, and log-transformed NT-proBNP at baseline. Histograms represent the frequency distribution of mtDNA copy number at baseline
×
×
In the stratified analysis, there was no evidence of interaction for the associations between mtDNA-CN and AF across all subgroups evaluated (Additional Files: Figure S1), except that they were stronger in hypertensive than in non-hypertensive participants from ARIC (p interaction = 0.03). Sensitivity analysis excluding non-Black and non-White participants in MESA, as well as additional analyses using MICE for missing mtDNA-CN in ARIC and IPAW to account for informative censoring in all cohorts, showed similar results (Additional Files: Table S4-S6).
Discussion
In three large population-based prospective cohort studies, mtDNA-CN was inversely associated with the risk of incident AF, independent of traditional risk factors. The association was not statistically different across race and sex groups. This novel association indicates a potential role of mitochondrial dysfunction in atrial arrhythmias and adds to the pathophysiological evidence from basic science studies supporting the role of mitochondrial mechanisms in the genesis of AF.
Animal models and molecular studies suggest that mitochondrial dysfunction is associated with adverse CVD outcomes and subclinical atherosclerosis [31, 32], and some of these associations have been confirmed in population-based studies. However, previous studies on mtDNA-CN and other CVD outcomes reported their results using different metrics, and the magnitude of reported estimates was incomparable. In ARIC, MESA, and CHS, low levels of mtDNA-CN were associated with increased risk of incident CVD (HR for a 1-SD decrease in mtDNA-CN, 1.29 [95% CI, 1.24–1.33]), coronary heart disease (HR for a 1-SD decrease in mtDNA-CN, 1.29 [1.24–1.33]), sudden cardiac death (HR comparing the 1st to the 5th quintiles of mtDNA-CN, 2.24 [1.58–3.19]), and all-cause mortality (HR comparing the 1st to the 5th quintiles of mtDNA-CN, 1.47 [95% CI, 1.33–1.62]) [10‐12]. Low levels of mtDNA-CN were also associated with CVD risk factors, including hypertension, diabetes, and chronic kidney disease [14‐16]. Since clinical CVD events and CVD risk factors are also risk factors for AF, the inverse associations between mtDNA-CN and AF could also be mediated through the traditional CVD pathways. As participants in our analysis were free of CHD at baseline and we adjusted for CVD risk factors, we identified an independent and statistically significant association between mtDNA-CN and incident AF after accounting for CVD and traditional risk factors. Furthermore, since low mtDNA-CN levels preceded the development of AF and other CVD events in ARIC, CHS, and MESA, maintaining CVD health may require adequate cell energy mechanisms and mitochondrial function for preserved cardiac contractility, electrical activity, and endothelial function.
Anzeige
AF is triggered by structural and electrophysiological remodeling changes in the atrial myocardium, which in turn adversely affect cardiac function and increase the risk of mortality, stroke, and peripheral embolism [33]. Risk factors of AF include older age, male sex, and the presence of clinical cardiomyopathy, coronary artery disease, and traditional CVD risk factors (hypertension, diabetes, obesity, and smoking) [25, 34, 35]. Our results suggest that mtDNA-CN may be a novel risk factor for AF. As low levels of mtDNA-CN are a marker for mitochondrial dysfunction and abnormal ATP production, our findings suggest that myocyte electrical activity could be compromised by mitochondrial dysfunction and insufficient energy supply.
The mechanisms underlying the association between mtDNA-CN and AF are unknown, but previous mechanistic research and in vitro studies provide some leads. Most of the energy for cardiomyocyte electrical activity and cardiac muscle contraction is supplied by the mitochondria through the oxidative phosphorylation pathway [18]. The generation of cellular reactive oxygen species (ROS) associated with mitochondrial dysfunction could increase arrhythmia susceptibility by affecting energy-dissipating ion channels and transporters, including the proteins involved in excitation-contraction coupling. Indeed, disrupted intracellular Ca2+ homeostasis has been shown to contribute to the pathogenesis of AF [17, 18, 36]. Increased ROS can also impair gap junction regulation and affect voltage-gated sodium-potassium channels, which increases electrical heterogeneity and causes early afterdepolarizations [18].
Apart from ROS, mitochondrial dysfunction impairs ATP synthesis, affecting cardiomyocyte energy metabolism, sarcolemmal and sarcoplasmic ion channel function, intracellular cation homeostasis, and membrane excitability, which are essential in maintaining the electrical activity of cardiac cells [36]. The reduced energy production promotes the opening of sarcolemmal KATP channels, which has arrhythmogenic effects by conferring shortened action potential duration and excitation wavelengths [37].
Some limitations of this study need to be considered. Differences in measurement methods in mtDNA-CN, AF, and covariates may contribute to the heterogeneity of the results across the 3 cohorts. Reassuringly, the direction of the association of mtDNA-CN and incident AF was consistent in ARIC, CHS, and MESA, adding weight to the validity of our findings. mtDNA-CN was collected from the peripheral blood and was thus not a direct measurement of mitochondrial function in atrial myocytes. However, mtDNA from the peripheral blood has been shown to be strongly correlated with mtDNA from cardiomyocyte (coefficient of correlation > 0.5) [13, 38]. Therefore, the mtDNA-CN from the peripheral blood could be used as a marker for myocardial mitochondrial function. Furthermore, mtDNA-CN was measured only at a single time point, and variability due to changes over time was not captured. Finally, we could not evaluate the association between mtDNA-CN with various subtypes of AF. Since AF was obtained primarily based on hospital discharge codes in all 3 studies, the diagnoses were mostly persistent or permanent forms of AF, whereas asymptomatic paroxysmal AF, the most common type of AF, is often undetected. Future studies with repeated measures of mtDNA markers may provide a better evaluation of longitudinal changes in mtDNA function and its impact on AF risk.
The strengths of this study include the prospective design, the long follow-up, the rigorous quality control procedures of the individual cohorts, the large sample size, and the heterogeneous composition of the study population, including men and women from multiple race/ethnicity groups and a wide age range from middle-aged adults to elderly participants.
Conclusion
In three prospective community-based cohorts, mtDNA-CN levels in the peripheral blood were inversely associated with the risk of AF independent of traditional risk factors. These findings implicate mtDNA-CN as a novel risk factor for AF. Further research is warranted to better understand the underlying mechanisms, to better characterize the dose-response shape of the association, and to evaluate the role of mtDNA-CN in the prevention and management of AF risk.
The authors thank the other investigators, the staff, and the participants of the ARIC, MESA, and CHS studies.
Ethics approval and consent to participate
Each study obtained approval from their institutional review boards at all centers (ARIC study: Johns Hopkins University, University of Mississippi, University of Minnesota, University of North Carolina at Chapel Hill, University of South Florida, Wake Forrest University; MESA study: University of California Los Angeles, University of Minnesota, Northwestern University, Columbia University, Wake Forrest University, Johns Hopkins University; CHS study: University of California Davis, Johns Hopkins University, Wake Forest University, University of Pittsburgh), and all participants provided written informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mitochondrial DNA copy number and incident atrial fibrillation
verfasst von
Di Zhao Traci M. Bartz Nona Sotoodehnia Wendy S. Post Susan R. Heckbert Alvaro Alonso Ryan J. Longchamps Christina A. Castellani Yun Soo Hong Jerome I. Rotter Henry J. Lin Brian O’Rourke Nathan Pankratz John A. Lane Stephanie Y. Yang Eliseo Guallar Dan E. Arking
Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.
Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.
Update Allgemeinmedizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
